

M14

Attorney Docket No. 08841.105022 (PHARM1030US) 04c



1614 (2) 03/25/02
1614

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Stuyver *et al.*

Serial No.: 10/023,637

Group Art Unit: Not Yet Assigned

Filed: December 17, 2001

Examiner: Not Yet Assigned

For: Antiviral Agents for Treatment of Flaviviridae Infections

Assistant Commissioner for Patents
Washington, DC 20231

RECEIVED
AUG 02 2002
TECH CENTER 1600/2900

March 21, 2002

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT


Sir:

Pursuant to the duty of disclosure under 37 CFR §§ 1.56, 1.97 and 1.98, Applicants cite the publication listed on the accompanying Form PTO-1449A. A copy of the listed reference is enclosed. The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under the applicable statutes, Rules of Practice in patent cases, or otherwise.

If the Examiner determines a fee is required, the Commissioner is authorized to charge any requisite fees associated with this paper to Deposit Account No. 11-0980.

RECEIVED

Respectfully submitted,


Josephine Young
Registration No. 48,308

AUG 4 2002

TECH CENTER 1600/2900


KING & SPALDING
191 Peachtree Street
Atlanta, GA 30303
404-572-4600 (Telephone)
404-572-5145 (Facsimile)

RECEIVED
AUG 02 2002
TECH CENTER 1600/2900



CERTIFICATE OF MAILING (37 CFR 1.8a)

I hereby certify that this Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.



Josephine Young

Date: March 21, 2002

Please type a plus sign (+) inside this box →

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/A/PTO		<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10/023,637
		Filing Date	December 17, 2001
		First Named Inventor	Stuyver et al.
		Group Art Unit	N/A
		Examiner Name	N/A
		Attorney Docket Number	PHAR1030US
Sheet	1	of	

RECEIVED
AUG 02 2002
TECH CENTER 1600/2900

MAR 26 2002
PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
AA	4,686,234			Nelson et al.	08-11-1987	
AB	5,026,687			Yarchoan et. al.	06-25-1991	
AC	5,496,546			Wang et. al.	03-05-1996	
AD	5,633,388			Diana et. al.	05-27-1997	
AE	5,665,728			Morris et. al.	09-09-1997	
AF	5,830,905			Diana et. al.	11-03-1998	
AG	5,846,964			Ozeki et. al.	12-08-1998	
AH	5,891,874			Colacino et al	04-06-1999	
AI	5,922,757			Chojkier et. al.	07-13-1999	
AJ	6,034,134			Gold et. al.	03-07-2000	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document DD-MM-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number	Kind Code ⁴ (if known)			
AK	WO	95/22538			Artis, D.R. et. al.	24-08-1995	
AL	WO	97/38689			Haeblerlin, B. et. al.	23-10-1997	
AM	WO	98/15563			Pankiewicz et. al.	16-04-1998	
AN	WO	00/33876			Lindner, J., et. al.	15-06-2000	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

MAR 26 2002
U.S. PATENT AND TRADEMARK OFFICE

Sheet

2 of 3

Complete if Known	
Application Number	10/023,637
Filing Date	December 17, 2001
First Named Inventor	Stuyver et al.
Group Art Unit	N/A
Examiner Name	N/A
Attorney Docket Number	PHAR1030US

RECEIVED

AUG 02 2002

TECH CENTER 1600/2900

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	BA	BATTAGLIA, A.M. et al. "Combination Therapy with Interferon and Ribavirin in the Treatment of Chronic Hepatitis C Infection." <i>Ann. Pharmacother.</i> 34:487-494, April 2000.	
	BB	BERENGUER, M. et al. "Hepatitis C virus in the transplant setting." <i>Antivir. Ther.</i> 3 (Suppl. 3):125-136, 1998.	
	BC	BULLINGHAM, R.E.S. et al. "Pharmacokinetics of Mycophenolate Mofetil (RS61443): A Short Review." <i>Transplant. Proc.</i> 28(2):925-929, April 1996.	
	BD	COLBY, T.D., et al. "Crystal structure of human type II inosine monophosphate dehydrogenase: Implications for ligand binding and drug design." <i>Proc. Nat. Acad. Sci. USA.</i> 96:3531-3536, March 1999.	
	BE	FRANKLIN, T.J., et al. "Human Colorectal Carcinoma Cell <i>In Vitro</i> as a Means to Assess the Metabolism of Analogs of Mycophenolic Acid." <i>Drug Metabolism and Disposition.</i> 25(3):367-370, 1997.	
	BF	HALE, M.D., et al. "The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation." <i>Clin. Pharmacol. & Ther.</i> 64(6):672-683, December 1998.	
	BG	JONES, D.F., et al. "Preparation and Antitumor Properties of Analogs and Derivatives of Mycophenolic Acid." <i>J. Med. Chem.</i> 14(4):305-311, 1971.	
	BH	KABAT, M.M., et al. "Synthesis of 5-β-D-Ribofuranosylnicotinamide and Its N-Methyl Derivative. The Isosteric and Isoelectronic Analogues of Nicotinamide Nucleoside." <i>J. Med. Chem.</i> 30:924-927, 1987.	
	BI	NELSON, P.H., et al. "Structure-Activity Relationships for Inhibition of Inosine Monophosphate Dehydrogenase by Nuclear Variants of Mycophenolic Acid." <i>J. Med. Chem.</i> 39:4181-4196, 1996.	

Examiner Signature	Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and do not consider. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ² See attached. Kind of U.S. Patent Document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449 A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

MAR 26 2002

PRAJDA & ASSOCIATES, LTD.

Sheet

3

of

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

RECEIVED

AUG 02 2002
TECH CENTER 1600
PHAR1030US

		<i>Complete if Known</i>	
		Application Number	10/023,637
		Filing Date	December 17, 2001
		First Named Inventor	Stuyver et al.
		Group Art Unit	N/A
		Examiner Name	N/A
		Attorney Docket Number	PHAR1030US

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
CA	NELSON, P.H., et al.	"Synthesis and Immunosuppressive Activity of Some Side-Chain Variants of Mycophenolic Acid." <i>J. Med. Chem.</i> 33:833-838, 1990.	
CB	PANKIEWICZ, et al.	"Efficient Synthesis of 5-(β-D-Ribofuranosyl) nicotinamide and It's α-Isomer". <i>J. Org. Chem.</i> 53(15):3473-3479, 1988.	
CC	PRAJDA, N., et al.	"Sequential Impact of Tiazofurin and Ribavirin on the Enzymic Program of the Bone Marrow." <i>Cancer Res.</i> 53(24):5982-5986, December 15, 1993.	
CD	SCHMOUDER, R., et al.	"Pharmacokinetics of ERL080A: A New Enteric Coated Formulation of Mycophenolic Acid-Sodium." <i>Transplantation.</i> 67(Suppl.):S203, 1999.	
CE	SHAW, L.M., et al.	"Mycophenolate Mofetil: A Report of the Consensus Panel." <i>Ther. Drug Monit.</i> 17(6):690-699, December 1995.	
CF	SINTCHAK, M.D., et al.	"Structure and Mechanism of Inosine Monophosphate Dehydrogenase in Complex with the Immunosuppressant Mycophenolic Acid." <i>Cell.</i> 85(6):921-930, June 14, 1996.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.